Primary Plasma Cell Leukemia

References

Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, Caers J, Gonsalves W, Schjesvold F, Merlini G, Lentzch S, Ocio E, Garderet L, Moreau P, Sonneveld P, Badros A, Gahrton G, Goldschmidt H, Tuchman S, Einsele H, Durie B, Wirk B, Musto P, Hayden P, Kaiser M, Miguel JS, Bladé J, Rajkumar SV, Mateos MV. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021 Dec 2;11(12):192. doi: 10.1038/s41408-021-00587-0. PMID: 34857730; PMCID: PMC8640034.

International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun;121(5):749-57. PMID: 12780789.

Avet-Loiseau H. Ultra high-risk myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010:489-93. doi: 10.1182/asheducation-2010.1.489. PMID: 21239841.

Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, Buadi FK, Lacy MQ, Kapoor P, Dingli D, Lust JA, Zeldenrust SR, Hayman SR, Kyle RA, Gertz MA, Kumar SK. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014 Aug 7;124(6):907-12. doi: 10.1182/blood-2014-03-565051. Epub 2014 Jun 23. PMID: 24957143; PMCID: PMC4126330.

Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008 May;22(5):1044-52. doi: 10.1038/leu.2008.4. Epub 2008 Jan 24. PMID: 18216867; PMCID: PMC3893817.

Frits van Rhee, Sharmilan Thanendrarajan, Carolina D. Schinke, Jeffery R. Sawyer, Adam Rosenthal, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, Mariam M. Boota, Clyde Bailey, Brian A Walker, Antje Hoering, Gareth Morgan, Maurizio Zangari, Faith E. Davies; EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab. Blood 2019; 134 (Supplement_1): 4569. doi: https://doi.org/10.1182/blood-2019-131887

Gonsalves WI, Buadi FK, Kumar SK. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). Eur J Haematol. 2018 Feb;100(2):215-217. doi: 10.1111/ejh.12986. Epub 2017 Nov 16. PMID: 29064593.